Kif15-IN-1CAS# 672926-32-8 |
- Vatalanib (PTK787) 2HCl
Catalog No.:BCC1111
CAS No.:212141-51-0
- Cediranib (AZD217)
Catalog No.:BCC1121
CAS No.:288383-20-0
- Lenvatinib (E7080)
Catalog No.:BCC1172
CAS No.:417716-92-8
- Tivozanib (AV-951)
Catalog No.:BCC1179
CAS No.:475108-18-0
- Brivanib (BMS-540215)
Catalog No.:BCC1231
CAS No.:649735-46-6
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 672926-32-8 | SDF | Download SDF |
PubChem ID | 60076300 | Appearance | Powder |
Formula | C20H22N4O5S | M.Wt | 430.48 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | DMSO : ≥ 100 mg/mL (232.30 mM) H2O : < 0.1 mg/mL (insoluble) *"≥" means soluble, but saturation unknown. | ||
Chemical Name | ethyl 2-[[(2S)-2-(2,4-dioxo-1H-quinazolin-3-yl)-3-methylbutanoyl]amino]-4-methyl-1,3-thiazole-5-carboxylate | ||
SMILES | CCOC(=O)C1=C(N=C(S1)NC(=O)C(C(C)C)N2C(=O)C3=CC=CC=C3NC2=O)C | ||
Standard InChIKey | CTQQKICGMSZCJL-AWEZNQCLSA-N | ||
Standard InChI | InChI=1S/C20H22N4O5S/c1-5-29-18(27)15-11(4)21-19(30-15)23-16(25)14(10(2)3)24-17(26)12-8-6-7-9-13(12)22-20(24)28/h6-10,14H,5H2,1-4H3,(H,22,28)(H,21,23,25)/t14-/m0/s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Kif15-IN-1 is an inhibitor of the mitotic kinesin Kif15, and is used for the research of cellular proliferative diseases.In Vitro:Kif15-IN-1 (Compound 10) is an inhibitor of the mitotic kinesin Hs Kif15, with the potential activities against cellular proliferative diseases such as cancer, hyperplasias, restenosis, cardiac hypertrophy, immune disorders and inflammation[1]. References: |
Kif15-IN-1 Dilution Calculator
Kif15-IN-1 Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.323 mL | 11.6149 mL | 23.2299 mL | 46.4598 mL | 58.0747 mL |
5 mM | 0.4646 mL | 2.323 mL | 4.646 mL | 9.292 mL | 11.6149 mL |
10 mM | 0.2323 mL | 1.1615 mL | 2.323 mL | 4.646 mL | 5.8075 mL |
50 mM | 0.0465 mL | 0.2323 mL | 0.4646 mL | 0.9292 mL | 1.1615 mL |
100 mM | 0.0232 mL | 0.1161 mL | 0.2323 mL | 0.4646 mL | 0.5807 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Kif15-IN-1 is a potent Kif15 kinesin inhibitor; inhibits cellular proliferation in tumor cell lines.
-
γDGG
Catalog No.:BCC6557
CAS No.:6729-55-1
- SKF 83959 hydrobromide
Catalog No.:BCC7251
CAS No.:67287-95-0
- SKF 81297 hydrobromide
Catalog No.:BCC7071
CAS No.:67287-39-2
- Cabraleadiol
Catalog No.:BCN4224
CAS No.:67253-01-4
- Boc-MLF
Catalog No.:BCC6061
CAS No.:67247-12-5
- 10(14)-Cadinene-4,5-diol
Catalog No.:BCN4223
CAS No.:672336-50-4
- Fenoldopam
Catalog No.:BCC4462
CAS No.:67227-56-9
- 5'-O-Dimethoxytrityl-N-benzoyl-desoxycytidine
Catalog No.:BCC8750
CAS No.:67219-55-0
- 2'-O-Coumaroyljuglanin
Catalog No.:BCN6559
CAS No.:67214-05-5
- SMER 3
Catalog No.:BCC6152
CAS No.:67200-34-4
- H-HoSer-OH
Catalog No.:BCC3247
CAS No.:672-15-1
- (±)-U-50488 hydrochloride
Catalog No.:BCC6665
CAS No.:67197-96-0
- Kif15-IN-2
Catalog No.:BCC5153
CAS No.:672926-33-9
- 3-O-(2'E ,4'Z-decadienoyl)-20-deoxyingenol
Catalog No.:BCN1382
CAS No.:672941-64-9
- Kansuinine E
Catalog No.:BCN3769
CAS No.:672945-84-5
- H-D-Phe-OH
Catalog No.:BCC3012
CAS No.:673-06-3
- H-Asp(OtBu)-OMe.HCl
Catalog No.:BCC2892
CAS No.:2673-19-0
- 2-Hydroxy-4-methoxybenzaldehyde
Catalog No.:BCN7798
CAS No.:673-22-3
- Kaurenoic acid
Catalog No.:BCN4600
CAS No.:6730-83-2
- 1,3,5-Trihydroxyxanthone
Catalog No.:BCN3357
CAS No.:6732-85-0
- Hexa-D-arginine
Catalog No.:BCC6269
CAS No.:673202-67-0
- (R,R)-Formoterol
Catalog No.:BCC1293
CAS No.:67346-49-0
- Pterokaurane R
Catalog No.:BCN4076
CAS No.:67349-43-3
- Catalposide
Catalog No.:BCN4225
CAS No.:6736-85-2
Dual inhibition of Kif15 by oxindole and quinazolinedione chemical probes.[Pubmed:30528696]
Bioorg Med Chem Lett. 2019 Jan 15;29(2):148-154.
The mitotic spindle is a microtubule-based machine that segregates a replicated set of chromosomes during cell division. Many cancer drugs alter or disrupt the microtubules that form the mitotic spindle. Microtubule-dependent molecular motors that function during mitosis are logical alternative mitotic targets for drug development. Eg5 (Kinesin-5) and Kif15 (Kinesin-12), in particular, are an attractive pair of motor proteins, as they work in concert to drive centrosome separation and promote spindle bipolarity. Furthermore, we hypothesize that the clinical failure of Eg5 inhibitors may be (in part) due to compensation by Kif15. In order to test this idea, we screened a small library of kinase inhibitors and identified GW108X, an oxindole that inhibits Kif15 in vitro. We show that GW108X has a distinct mechanism of action compared with a commercially available Kif15 inhibitor, Kif15-IN-1 and may serve as a lead with which to further develop Kif15 inhibitors as clinically relevant agents.